Flunixin meglumin, Cyclooxygenase inhibitor (ab145689)

Overview

  • Product name

    Flunixin meglumin, Cyclooxygenase inhibitor
  • Description

    Cyclooxygenase inhibitor used as an analgesic agent with anti-inflammatory and antipyretic activity
  • Alternative names

    • 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylate, 1-deoxy-1-(methylamino)-D-glucitol(1:1)
    • Banamine
    • Finadyne
    • Flunixin meglumine
    • FM
    • FNX
    • Megluxin
    see all
  • Biological description

    Non-narcotic, non-steroidal anti-inflammatory drug (NSAID) used as an analgesic agent with antipyretic activities. Cyclooxygenase (COX) inhibitor. Used in animals for the management of intestinal ischaemia, colic, and endotoxemia.

  • Purity

    > 99%
  • CAS Number

    42461-84-7
  • Chemical structure

    Chemical Structure

Properties

  • Molecular weight

    491.46
  • Molecular formula

    C14H11F3N2O2.C7H17NO5
  • Storage instructions

    Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in DMSO to 100 mM, in water to 100 mM and in ethanol to 10 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Toxic, refer to SDS for further information.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • Source

    Synthetic

References

This product has been referenced in:

  • Avila TV  et al. Hepatic effects of flunixin-meglumin in LPS-induced sepsis. Fundam Clin Pharmacol 24:759-69 (2010). Read more (PubMed: 20030736) »
  • Bryant CE  et al. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res 64:211-5 (2003). Read more (PubMed: 12602591) »
  • Miyazaki Y  et al. Possible active transport mechanism in pharmacokinetics of flunixin-meglumin in rabbits. J Vet Med Sci 63:885-8 (2001). Read more (PubMed: 11558544) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab145689.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up